TY - JOUR
T1 - Impact of Atopic Dermatitis Lesion Location on Quality of Life in Adult Patients in a Real-world Study
AU - Lio, Peter A.
AU - Wollenberg, Andreas
AU - Thyssen, Jacob P.
AU - Pierce, Evangeline J.
AU - Rueda, Maria Jose
AU - DeLozier, Amy M.
AU - Terres, Jorge Alfonso Ross
AU - Anderson, Peter
AU - Milligan, Gary
AU - Piercy, James
AU - Silverberg, Jonathan I.
AU - Paul, Carle
N1 - Publisher Copyright:
© 2020 Journal of Drugs in Dermatology. All rights reserved.
PY - 2020/10
Y1 - 2020/10
N2 - Background: Atopic dermatitis (AD) has a negative impact on patients’ quality of life (QoL). Objective: To report the impact of specific AD lesion locations on QoL in adult patients with AD using real-world data. Methods: The Adelphi US Disease Specific Programme was conducted between January–April 2018. Physicians documented patient demographics/characteristics, AD lesion locations, and body surface area; patients completed questionnaires reporting the impact of lesion locations on QoL. Results: AD severity was moderate in 51.6% of patients and severe in 6.0%. Lesions were commonly identified in more than one location. All AD lesion locations impacted QoL. Visible areas were most bothersome, including head/neck (68%), hands/fingers (58%), front (30%), upper extremities (22%), and lower extremities (16%), with statistically significant associations for a number of Dermatology with Life those Quality that are Index most (DLQI) visible/accessible. items. Itch, soreness, Lesions pain, onDo the and head/neck Not stingingCopy are and also hands/fingers associated (58%) with a demonstrated number of body an areas increased but in impact particular onthe Conclusions: anxiety and In depression patients with dimension AD, quality of the of life EuroQol wasPenalties most 5-Dimension affected in tool. patients Apply with lesions in visible areas, including head/neck, hands/ fingers, and upper extremities, with statistically significant associations for a number of DLQI domains. Physicians should be aware of the burden of AD lesions on QoL and consider having conversations with patients to better understand the impact of these lesions. Prior presentation: 28th Annual European Academy of Dermatology and Venereology Congress; 9–13 October 2019, Madrid, Spain. Poster number P0233.
AB - Background: Atopic dermatitis (AD) has a negative impact on patients’ quality of life (QoL). Objective: To report the impact of specific AD lesion locations on QoL in adult patients with AD using real-world data. Methods: The Adelphi US Disease Specific Programme was conducted between January–April 2018. Physicians documented patient demographics/characteristics, AD lesion locations, and body surface area; patients completed questionnaires reporting the impact of lesion locations on QoL. Results: AD severity was moderate in 51.6% of patients and severe in 6.0%. Lesions were commonly identified in more than one location. All AD lesion locations impacted QoL. Visible areas were most bothersome, including head/neck (68%), hands/fingers (58%), front (30%), upper extremities (22%), and lower extremities (16%), with statistically significant associations for a number of Dermatology with Life those Quality that are Index most (DLQI) visible/accessible. items. Itch, soreness, Lesions pain, onDo the and head/neck Not stingingCopy are and also hands/fingers associated (58%) with a demonstrated number of body an areas increased but in impact particular onthe Conclusions: anxiety and In depression patients with dimension AD, quality of the of life EuroQol wasPenalties most 5-Dimension affected in tool. patients Apply with lesions in visible areas, including head/neck, hands/ fingers, and upper extremities, with statistically significant associations for a number of DLQI domains. Physicians should be aware of the burden of AD lesions on QoL and consider having conversations with patients to better understand the impact of these lesions. Prior presentation: 28th Annual European Academy of Dermatology and Venereology Congress; 9–13 October 2019, Madrid, Spain. Poster number P0233.
UR - http://www.scopus.com/inward/record.url?scp=85092682767&partnerID=8YFLogxK
U2 - 10.36849/JDD.2020.5422
DO - 10.36849/JDD.2020.5422
M3 - Article
C2 - 33026770
AN - SCOPUS:85092682767
SN - 1545-9616
VL - 19
SP - 943
EP - 948
JO - Journal of Drugs in Dermatology
JF - Journal of Drugs in Dermatology
IS - 10
ER -